- Home
- AVBP vs CSTL Comparison
AVBP vs CSTL Comparison
Compare AVBP & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBP
- CSTL
- Stock Information
- Founded
- AVBP 2021
- CSTL 2007
- Country
- AVBP United States
- CSTL United States
- Employees
- AVBP N/A
- CSTL N/A
- Industry
- AVBP
- CSTL Medical Specialities
- Sector
- AVBP
- CSTL Health Care
- Exchange
- AVBP NYSE
- CSTL Nasdaq
- Market Cap
- AVBP 925.7M
- CSTL 848.1M
- IPO Year
- AVBP 2024
- CSTL 2019
- Fundamental
- Price
- AVBP $27.52
- CSTL $28.61
- Analyst Decision
- AVBP Strong Buy
- CSTL Strong Buy
- Analyst Count
- AVBP 5
- CSTL 6
- Target Price
- AVBP $36.80
- CSTL $40.33
- AVG Volume (30 Days)
- AVBP 152.3K
- CSTL 289.3K
- Earning Date
- AVBP 02-02-2025
- CSTL 02-26-2025
- Dividend Yield
- AVBP N/A
- CSTL N/A
- EPS Growth
- AVBP N/A
- CSTL N/A
- EPS
- AVBP N/A
- CSTL 0.21
- Revenue
- AVBP N/A
- CSTL $311,878,000.00
- Revenue This Year
- AVBP N/A
- CSTL $51.36
- Revenue Next Year
- AVBP N/A
- CSTL N/A
- P/E Ratio
- AVBP N/A
- CSTL $136.00
- Revenue Growth
- AVBP N/A
- CSTL 62.43
- 52 Week Low
- AVBP $14.35
- CSTL $16.97
- 52 Week High
- AVBP $36.37
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- AVBP 50.18
- CSTL 49.85
- Support Level
- AVBP $26.36
- CSTL $25.82
- Resistance Level
- AVBP $27.67
- CSTL $28.08
- Average True Range (ATR)
- AVBP 1.27
- CSTL 1.23
- MACD
- AVBP 0.18
- CSTL 0.10
- Stochastic Oscillator
- AVBP 71.82
- CSTL 71.54
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.